United Therapeutics reported results for the 2026 quarter with revenue of $783.3M, net income of $333M and diluted EPS of $7.27. Revenue declined modestly versus the prior-year quarter while profit and EPS increased.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$783.3M$798.6M(1.9%) | Net income²$333M$309.5M7.6% | Diluted EPS³$7.27$6.4113.4% |
¹ Reported as “Total revenues”. ² Reported as “Net income”. ³ Reported as “Diluted income per common share”.
Business Highlights
- Revenue trend: Total revenues were down about 2% year over year; growth in Tyvaso DPI was offset by declines in Nebulized Tyvaso and Remodulin.
- Channel & geographic mix: U.S. sales drove volumes for Tyvaso and other products while rest-of-world sales declined.
- Regulatory and clinical progress: Positive clinical results for TETON-1/2 (Nebulized Tyvaso for IPF) and ADVANCE OUTCOMES for ralinepag, with sNDAs/NDAs submitted.
- Operational expansion: Building manufacturing and drug product facilities — including an RTP ralinepag DPI site and DPFs in Minnesota and Texas — and scaling EVLP services.
- Pipeline and M&A: Advancing treprostinil SMI, ralinepag DPI and triple therapy programs; recent acquisitions (Miromatrix, IVIVA, Thymmune) expand the organ and regenerative platform.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.